Bristol-Myers Squibb Set to Report Strong Q1 Earnings Growth
With a market capitalization of $102.7 billion, Bristol-Myers Squibb Company (BMY) stands as a prominent global biopharmaceutical entity focused on developing innovative treatments for serious diseases, notably in oncology, immunology, and cardiovascular health. The company’s robust lineup of market-leading drugs, including Opdivo and Eliquis, reflects its commitment to addressing the needs of high-need patient populations through strategic acquisitions, advanced research, and development efforts.
Anticipated Earnings Announcement
BMY is scheduled to reveal its fiscal Q1 2025 earnings results on Thursday, April 24, prior to market opening. Analysts predict the company will report an adjusted EPS of $1.56 per share, representing a substantial increase of 135.5% from the loss of $4.40 per share that occurred in the same quarter last year. Over the past four quarters, BMY has consistently outperformed Wall Street’s earnings expectations, surpassing the consensus adjusted EPS estimate in Q4 2024 by 14.4%.
2025 Financial Projections
Looking ahead to fiscal 2025, analysts estimate that the biopharmaceutical giant will report an adjusted EPS of $6.78, a staggering increase of 489.6% from the $1.15 generated in fiscal 2024.
Market Performance Overview
Over the past year, BMY has lagged behind broader market trends, with its shares rising slightly while the S&P 500 Index ($SPX) posted a 2.1% gain. Notably, BMY has outdone the Health Care Select Sector SPDR Fund (XLV), which experienced a 4.7% decline during the same timeframe.
Q4 2024 Results and Market Reaction
Despite announcing a better-than-expected Q4 2024 adjusted EPS of $1.67 and revenues reaching $12.3 billion, BMY shares fell by 3.8% on February 6. The company’s guidance for 2025 anticipates revenues around $45.5 billion and an adjusted EPS between $6.55 and $6.85, both figures falling short of analyst forecasts. Investors expressed concern regarding declining gross margins alongside increased R&D expenditures, as well as ongoing challenges with the Legacy Portfolio amid growth from newer products, which contributed to market uncertainty.
Analyst Outlook
The consensus among analysts for BMY is moderately optimistic, reflected in a “Moderate Buy” rating. Of the 24 analysts monitoring the stock, opinions include six “Strong Buys,” 17 “Holds,” and one “Strong Sell.” The average price target for BMY stands at $60, indicating a potential upside of 18.9% from current trading levels.
On the date of publication,
Sohini Mondal
did not hold (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are intended for informational purposes only. For more details, please review the Barchart Disclosure Policy
here.
More news from Barchart
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
